Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech, Inc. (KRYS) reported that director Julian S. Gangolli received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to his continued service on the Board and earlier vesting conditions under the company’s Non-Employee Director Compensation Policy.
Krystal Biotech, Inc. (KRYS) insider Suma Krishnan, a director, President of R&D, and ten percent owner, reported open-market sales of 25,000 shares of common stock on September 4, 2026. The sales were executed in multiple trades at prices within ranges from $353.98 to $366.91 per share and were made under a Rule 10b5-1 trading plan adopted on September 4, 2025, which has now reached its maximum share amount and terminated. Following these transactions, Krishnan continues to hold shares indirectly through several family trusts, including 90,000 shares held by the Krishnan Spousal Trust, 51,010 shares held by the Suma Mani Krishnan Trust, and 50,000 shares held by the Krishnan Family Trust.
Krystal Biotech, Inc. (KRYS) reports that President and CEO, director, and more-than-10% owner Krishnan Krish S sold 25,000 shares of common stock on September 4, 2026 in multiple open-market transactions around the mid-$350s per share, under a Rule 10b5-1 trading plan adopted September 4, 2025 that has now reached its maximum and terminated. He continues to hold shares indirectly through family trusts, including 90,000, 77,710, and 50,000 shares, respectively.
Krystal Biotech, Inc. (KRYS) is the issuer of common stock that Suma Krishnan has notified under Rule 144 of an intention to sell. The notice covers up to 25,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares are described as Founders Shares, acquired from Krystal Biotech on March 31, 2017. The filing lists an aggregate market value for the planned sale of approximately $9,286,750. The form indicates no other Rule 144 sales by the filer in the past three months.
Krystal Biotech, Inc. (KRYS) received a Rule 144 notice from insider Krish Krishnan covering a proposed sale of 25,000 shares of common stock through Morgan Stanley Smith Barney LLC. The shares are identified as founders shares that were originally acquired from the issuer on March 31, 2017.
Krystal Biotech, Inc. director Dino A. Rossi reported dispositions of Common Stock on August 14, 2026. He made a bona fide gift of 3,691 shares to a charitable donor-advised fund and sold 25,000 shares in multiple open-market transactions at weighted average prices ranging from $325.5985 to $333.23 per share, as detailed in trade-level footnotes.
Krystal Biotech reported solid profitability and growth for the quarter ended June 30, 2026. Product revenue, net was $119.2 million versus $96.0 million a year earlier, driven by VYJUVEK, which generated $119.2 million in global net product revenue in the quarter and $965.9 million since launch, with a gross margin of 95%. Quarterly net income was $54.8 million, or $1.85 basic and $1.79 diluted EPS, compared with $38.3 million and EPS of $1.33 basic and $1.29 diluted in the prior-year quarter. For the first six months of 2026, product revenue, net totaled $235.6 million and net income was $110.7 million.
Cash, cash equivalents and investments totaled $1.1 billion as of June 30, 2026, supporting a broad pipeline. Key upcoming milestones include a registrational IOLITE readout for KB803 in 4Q 2026, continued EMERALD-1 enrollment for KB801, advancement of KB407 toward a registrational study in 2027, interim data for KB111 and KB407/KB408 programs, and further development of KB707 in NSCLC and Gorlin syndrome. The company guided full-year 2026 non-GAAP combined R&D and SG&A expense to $175.0–$195.0 million, excluding stock-based compensation, while continuing global VYJUVEK expansion, including anticipated launches in Spain and Italy in 2026.
Krystal Biotech, Inc. reported that on July 21, 2026 it submitted a response to a U.S. Patent and Trademark Office Office Action for a published patent application covering KB801, its investigational gene therapy for neurotrophic keratitis. The response includes data from a single patient in a discontinued clinical study who, after receiving KB801, experienced complete closure of a persistent corneal epithelial defect. The study was discontinued to advance KB801 into a pivotal trial, and no safety concerns or serious adverse events were observed in patients treated in that study.
Krystal Biotech explains that this single-patient observation had not been previously shared and is being disclosed so investors and other stakeholders have equal access to information that will appear in the patent prosecution record. The company emphasizes that this anecdotal result is not top-line data from any clinical trial and that no conclusions about the safety or efficacy of KB801 should be drawn from it. Krystal Biotech does not plan to provide subject-level updates from the discontinued study and expects to report pivotal trial results in the ordinary course. The described information and an image of the defect closure, furnished as an exhibit, are treated as furnished rather than filed under the Exchange Act and are not incorporated into other SEC reports except by specific reference, and the company notes forward-looking statements remain subject to clinical and other risks outlined in its risk factor disclosures.